Demystifying Drug Dosing In Renal Dysfunction

Chronic kidney disease affects approximately 10% of adults in the United States or approximately 20 million individuals. Further, recent studies have shown that improper dosing in patients with renal dysfunction occurs over 20% of the time. ASHP’s Demystifying Drug Dosing in Renal Dysfunction addresses the persistent and challenging problem of dosing medications for patients with renal insufficiency and dysfunction.

"Chronic kidney disease affects approximately 30 million adults in the United States. Demystifying Drug Dosing in Renal Dysfunction supports your clinical decision process with guidance on dosage adjustments and monitoring in renal dysfunction for medications, subpopulations, and renal replacement modalities. This time-saving resource provides helpful tips and support for a range of clinical situations, including antiepileptics, cardiovascular disease, co-morbidities associated with chronic kidney disease, critical illness, infectious diseases, oncology, pain management, pediatrics, psychiatry, therapeutic plasma exchange, and transplantation"--Publisher's description.

With Demystifying Drug Dosing in Obese Patients, that resource you need is here, delivering: Fully-referenced dosing recommendations for specific drugs Dedicated chapters on antimicrobial dosing, anticoagulants and antiplatelets, antiepileptics, analgesics, antineoplastic medicines, and more Guidance on immunosuppression and medication absorption in bariatric surgery Tips for adult, pediatric, ambulatory, acute, and critical care Pharmacokinetic parameters in obese patients

This text provides tables of factors for determining drug dosage. This edition covers 30 new drugs, including a new section on quinolenes. Dosing during continuous arteriovenous haemofiltration and other forms of extracorporeal treatment are included.

50th Anniversary Edition of the groundbreaking case-based pharmacotherapy text, now a convenient two-volume set. Celebrating 50 years of excellence, Applied Therapeutics, 12th Edition, features contributions from more than 200 experienced clinicians. This acclaimed case-based approach promotes mastery and application of the fundamentals of drug therapeutics, guiding users from General Principles to specific disease coverage with accompanying problem-solving techniques that help users devise effective evidence-based drug treatment plans. Now in full color, the 12th Edition has been thoroughly updated throughout to reflect the ever-changing spectrum of drug knowledge and therapeutic approaches. New chapters ensure contemporary relevance and up-to-date IPE case studies train users to think like clinicians and confidently prepare for practice.

Praised by practitioners, students and instructors for its engaging approach to teaching a very complex subject, Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing, has long been the go-to guide for learning how to calculate opioid conversions. Now in its second edition, this reference is a must-have for clinicians involved in pain management at all levels. Written by pain management expert Mary Lynn McPherson, PharmD, MA, MDE, BCPS, CPE, Demystifying Opioid Conversion Calculations focuses on the calculations that practitioners use in actual practice, providing realistic scenarios for decision making. The revised edition covers the entire spectrum of opioid analgesics used to manage patients with moderate-to-severe pain and serious life­-limiting illnesses.

Everything pharmacists and pharmacy students need to know about drug information management A Doody's Core Title for 2023! Drug Information: A Guide for Pharmacists provides you with the tools you need to to research, interpret, evaluate, collate, and disseminate drug information in the most effective and efficient manner possible. This trusted resource addresses essential topics such as formulating an effective response and recommendations for information, evaluation of drug literature, the application of statistical analysis in the biomedical sciences, medications and patient safety, investigational drugs, and more. This updated seventh edition also addresses other important issues such as the legal and ethical considerations of providing information, how to respond to requests for information, and how to determine what information should be made available.

Dr. Aranda is an top expert in the area of pharmacology in the pediatric population. His issue has knowledgeable authors presenting clinical reviews on a wide variety of topics, from "hot areas " of drug therapy to drug abuse in children as well as current areas of debate in neonatal drug therapy. Articles are devoted to the following topics: New and Current Drug Therapies For Asthma In Children; Psychopharmacology Of Bipolar Disorders in Children and Adolescents; Designer Drug Abuse in School Children; Dietary Supplements in Children; Anticoagulant Therapies in Children; New Antimicrobials for Gram-Positive Infections in Children; Probiotics in Newborns And Children; Anticonvulsant Therapies in Newborns and Children; Immunomodulator Drug Therapies in Inflammatory Bowel Diseases in Children; Non-Steroidal Anti-Inflammatory Drugs in Newborns and Children; Metformin Use in Pre-Diabetic Children and Adolescents; Problems in Drug Dosing of Obese Children; Inhaled Drugs and Systemic Steroids for Bronchopulmonary Dysplasia; Antifungal Drugs in Newborns and Children; Antiviral Drugs In Newborns and Children; and Development of Drug Therapies for Newborns and Children. Readers will come away with the latest clinical information to help inform them when diagnosing and prescribing for children.

Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine.